Neonatal Bladder-derived Mesenchymal Stem Cells Ameliorate Bladder Dysfunction in Diabetic Rat Models

Area of Science:

• Regenerative Medicine
• Urology
• Stem Cell Biology

Background:

• Diabetic bladder dysfunction (DBD) is a common complication of diabetes mellitus.
• Current treatments for DBD have limited efficacy and significant side effects.
• Mesenchymal stem cells (MSCs) have shown potential in treating various conditions due to their regenerative properties.

Purpose of the Study:

• To investigate the therapeutic potential of a novel mesenchymal stem cell type derived from the neonatal bladder (nMSC-B) for treating diabetic bladder dysfunction (DBD).
• To evaluate the effects of nMSC-B transplantation on bladder function and structure in a rat model of type-1 diabetes.

Main Methods:

• Neonatal bladder-derived mesenchymal stem cells (nMSC-B) were harvested and cultured.
• Type-1 diabetic rats were induced using Streptozocin (STZ).
• nMSC-B were administered via intraperitoneal injection or direct detrusor injection, compared to control groups.

Main Results:

• nMSC-B treatment significantly improved voiding function, including maximum voiding pressure (MVP).
• Histopathological analysis revealed recovery of bladder smooth muscle and urothelium, with reduced fibrosis in stem cell-treated groups.
• Direct detrusor injection of nMSC-B showed more pronounced recovery compared to intraperitoneal administration.

Conclusions:

• Neonatal bladder-derived mesenchymal stem cells (nMSC-B) demonstrate significant therapeutic effects in ameliorating diabetic bladder dysfunction (DBD).
• nMSC-B represent a promising and effective treatment strategy for DBD.
• Further research into nMSC-B therapy for urological conditions is warranted.